Myelodysplastic syndrome accompanied by basophilia and eosinophilia with t(5;12)(q31;p13) by Katsura Yukitaka et al.
Myelodysplastic syndrome accompanied by
basophilia and eosinophilia with
t(5;12)(q31;p13)
著者 Katsura Yukitaka, Suzukawa Kazumi, Nanmoku
Toru, Nemoto Noriko, Machino Takayuki, Obara
Naoshi, Okoshi Yasushi, Mukai-Yamamoto Harumi,
Hasegawa Yuichi, Kojima Hiroshi, Kawakami
Yasushi, Nagasawa Toshiro
journal or
publication title
Cancer Genetics and Cytogenetics
volume 178
number 1
page range 85-88
year 2007-10
権利 (C)2007 Elsevier Inc.
URL http://hdl.handle.net/2241/97858
doi: 10.1016/j.cancergencyto.2007.05.020
Letter to the editor 
    
Myelodysplastic syndrome accompanied by basophilia and eosinophilia with 
t(5;12)(q31;p13) 
 
Yukitaka Katsura a , Kazumi Suzukawa a,b,∗ , Toru Nanmoku c , Noriko Nemoto a , 
Takayuki Machino a , Naoshi Obara a , Yasushi Okoshi a , Harumi Yamamoto 
Mukai a , Yuichi Hasegawa a , Hiroshi Kojima a , Yasushi Kawakami b , Toshiro 
Nagasawa a . 
 
a Department of Clinical and Experimental Hematology, Graduate School of 
Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan 
b Department of Clinical Pathology, Graduate School of Comprehensive 
Human Sciences, University of Tsukuba, Ibaraki, Japan,  
c Central Laboratory, Tsukuba University Hospital, Ibaraki, Japan 
 
∗Corresponding author Kazumi Suzukawa  
  Department of Clinical and Experimental Hematology, 
  Major of Advanced Medical Applications, 
  Graduate School of Comprehensive Human Sciences, 
  University of Tsukuba, 
  Tennoudai, 1-1-1, Tsukuba, Ibaraki 
  305-8575, Japan 
Telephone/FAX: +81-029-853-3054  
E-mail: suzukazu@md.tsukuba.ac.jp
 
 
 1
The t(5;12)(q31-35;p12-13) translocation is rare among 
cytogenetically categorized myeloid diseases.  Here we describe a case of 
MDS with basophilia followed by leukocytosis, basophilia and eosinophilia 
with t(5;12)(q31;p13).   
 A 44-year-old man was referred to Tsukuba University Hospital due 
to severe anemia and thrombocytopenia in August 2005.  Peripheral blood 
showed hemoglobin 4.5 gm/dl with MCV 109 fl, platelets 73 × 10 9  l -1  and white 
blood cells 4.9 × 10 9  l -1  with 23% basophils, 3% eosinophils and 0% blasts.  
Bone marrow was slightly hypocellular marrow with trilineage dysplasia.  
Cytogenetic examination of the bone marrow cells revealed 46,XY.  A 
diagnosis of MDS-RAEB2 was made according to the WHO classification.  
Two months later, his white blood cell (WBC) count gradually increased with 
emerging eosinophilia.  Peripheral blood showed white blood cells 27.5 × 10 9  
l -1  with 54% basophils, 29% eosinophils and 0% blasts.  Bone marrow was 
hypercellular with relative increase of immature cells.  Cytogenetic 
exmination of his bone marrow cells revealed 47,XY,t(5;12)(q31;p13), 
+8[5]/46,XY[15].  We tried short-term administration of Imatinib in our case 
but saw no response.  We next started administration of hydroxyurea.  The 
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WBC count temporarily increased to maximum of 87.3 × 10 9  l -1 , and then 
gradually decreased.  Three months later, he received unrelated allogenic 
bone marrow transplantation following a myeloablative preparation regimen 
of cyclophosphamide (120mg/kg) and total body irradiation (12Gy) in March 
2006.  Currently, he is healthy with negative test for t(5;12)(q31;p13).  
Recently, human long fatty acyl CoA synthetase gene, ACS2, on 5q31 
was identified as a fusion partner of ETV6 in acute myeloid leukemia (AML) 
and MDS cases with t(5;12)(q31;p13)[1]. We also performed RT-PCR for 
ETV6-ACS2 from the bone marrow cells following the published method [1] 
and an amplified DNA fragment was detected (fig.1A).  DNA sequencing of 
the DNA fragment revealed an out-frame fusion of exon 1 of ETV6 gene to 
exon 1 of ACS2 gene (fig.1B).  Expressions of interleukin-3 (IL-3) or 
nterleukin-5 (IL-5) were detected in the bone marrow cells of our case while 
no expression was seen in controls (fig.1C,D), which may be related to the 
cause of eosinophilia or basophilia as previously suggested [2, 3].   
We have summarized the published reports of hematological disorders 
accompanied by t(5;12)(q31;p12-13) (Table 1). A remarkable male 
preponderance (14/15) can be seen.  Only two cases (case 8 and case 16) were 
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accompanied by basophilia (Table 1, [1, 4]).  On the other hand, 15 of 18 cases 
(83%) were accompanied by eosinophilia (Table.1, [1-13]).  ETV6-ACS2 fusion 
gene was identified in seven cases.  Eight cases seem to be classified as MDS 
/ MPD by WHO criteria.  These cases may be typified as a distinct subgroup 
of myeloid disorders.  Another nonrandom translocation which involves the 
short arm of the chromosome 12 and the long arm of the chromosome 5 is the 
t(5;12)(q33 ;p13) [14].  The translocation juxtaposes the ETV6 gene with the 
platelet-derived growth factor receptor β (PDGFRβ) gene.  It is of clinical 
importance that imanitib mesylate is effective for patients with 
rearrangement of the PDGFRβ gene [15].  Our patient received a course of 
imatinib without response.  It is important to determine the precise 
breakpoint or identify the fusion gene in hematological malignancy with 
t(5;12) to ensure an appropriate choice of therapy.  
We experienced a rare case of MDS with t(5;12)(q31;p13) with 
basophilia and eosinophilia.  Further studies are needed to understand the 
precise mechanism of disease by the translocation or the resultant fusion gene.
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Figure captions 
Fig. 1. (A) RT-PCR amplification of ETV6-ACS2 fusion.  Lane 1: 50bp ladder 
marker; lane 2: bone marrow at initial presentation in August 2005; lane 3: 
bone marrow with basophilia and eosinophilia in December 2005; lane 4: bone 
marrow after alloBMT in April 2006. (B) DNA sequencing of the RT-PCR 
product revealed a fusion between ETV6 exon 1 and ACS2 exon 1.  Arrows 
indicate the breakpoint.  Lower line represents putative coding region of 
ETV6-ACS2 fusion[1]. (C,D) RT-PCR of IL-3 (C) and IL-5 (D) genes. Lane 1: 
50bp ladder marker; lane 2: bone marrow at initial presentation in August 
2005; lane 3: bone marrow with basophilia and eosinophilia in December 2005; 
lane 4: bone marrow after alloBMT in April 2006; lane 5 and 6: bone marrow 
from lymphoma patients without involvement.  Transcription of IL-3 was 
detected as a 169 bp fragment.  The 394 bp fragment is due to an 
amplification of contaminated genomic DNA[2]. 
Table 1 Cases of myeloproliferative disorders with t(5;12)(q31;p12-13) Table 1 Cases of myeloproliferative disorders with t(5;12)(q31;p12-13) 
WBC Hb Platelet
No. Diagnosis Age/Sex
(x109/L) Eo(%) Ba(%) (g/dL) (x109/L)
Karyotype 
Detection of 
ETV6-ACS2 
Therapy 
Follow-up
(mons) 
Status Ref. 
1 aCML 49/M NG increase NG NG NG 46,XY,t(5;12)(q31;p13) RT-PCR NG NG NG [2] 
2 aCML 34/M NG increase NG NG NG 46,XY,t(5;12)(q31;p12-p13) ND NG 14+ alive [6] 
3 aCML 53/M 49.0 0 0.88 5.6mM 52 47,XY,t(5;12)(q31;p12),+10 ND polychemo-therapy 9 dead of sepsis [7] 
4 aCML 40/M 46.9 12 1.2 6.8mM 52 46,XY,t(5;12)(q31;p12) ND allo-SCT 14 dead [7] 
5 HES (aCML?) 43M 26.5 18 NG NG NG 46,XY,t(5;12)(q31;p12) ND HU,VCR,allo-SCT 48 dead of fungal infection [8] 
6 aCML/CMMoL 16/M 46.4 6 3 12.0 213 46,XY,t(5;12)(q31;p12) ND IFN,HU NG NG [9] 
7 CMMoL 41/M 32.4 11 2.6 15.2 202 46,XY,t(5;12)(q31;p12) ND HU 31+ alive [10] 
8 MDS 68/F 8.8 3 69 8.4 37.5 46,XX,t(5;12)(q31;p13) RT-PCR AraC NG dead of sepsis [1] 
9 MDS 27/M 41.1 42 NG NG NG 46,XY,t(5;12)(q31;p13) RT-PCR NG 1 dead of sepsis [1] 
10 MDS 8/F 33.7 6.2 1.0 12.9 322 46,XX,t(5;12)(q31;p12-p13)  ND HU 84+ alive [3] 
11 MDS 7M NG increase NG NG NG 46,XY,t(5;12)(q31;p13), -8,+12 ND HU,IFN 48+ alive [11] 
12 EoL 59/M 136.0 94 1.3 12.5 116 46,XY,t(5;12)(q31;p12) ND HU,BU 3 dead of brain stroke [5] 
13 AML 53/M 59.5 69 3 NG 59.5 46,XY,t(5;12)(q31;p13) RT-PCR polychemo-therapy 9 dead of eos. infiltration [1] 
14 MPD→EoL 59/M 20.9 10 3 4.2 40 
46,XY,t(5;12)(q31;p12), 
t(19;21)(p13;q22) 
ND BU,6TG 3 dead [12] 
15 AML-relapse 30/M 41.1 42 2.4 13.4 370 46,XY,t(5;12)(q31;p12) ND NG 1 dead of sepsis [13] 
16 PV 29/M 11.2 16 NG 21.0 522 46,XY,t(5;12)(q23-31;p13) FISH HU 42+ alive [4] 
   9.6 15 15 16.5 484        
17 PV/AML 31/F 18.2 NG NG 13.0 278 46,XX,t(5;12)(q23-31;p13) FISH HU, purinethol, AraC 11 dead of hemorrhage [4] 
18 MDS 44/M 22.7 39 42 5.5 85 47,XY,t(5;12)(q31;p13),+8 RT-PCR HU,AraC,STI571, alloSCT 8+ alive Present case 
Abbreviations: Eo,eosinophils; Baso,basophils; Mono,monocytes: NG,not given; aCML,atypical chronic myeloid leukemia; MDS, myelodysplastic syndrome; AML, acute leukemia; EoL, Eosinophilic leukemia; alloSCT, 
allogenic stem cell transplantation; IFN, interferon; HU, hydroxyurea; BU, busulfan; VCR, vincristine; ND, no determination 
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